Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 04/08/26
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 InterferenceGlobeNewsWire • 03/27/26
Editas Medicine, Inc. (EDIT) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha • 03/12/26
EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/YZacks Investment Research • 03/10/26
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business UpdatesGlobeNewsWire • 03/09/26
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025GlobeNewsWire • 11/03/25
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual CongressGlobeNewsWire • 10/09/25
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor ConferencesGlobeNewsWire • 10/06/25
Editas Nominates EDIT-401 as Lead In Vivo Therapy for High CholesterolZacks Investment Research • 09/03/25
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development CandidateGlobeNewsWire • 09/02/25
Editas Medicine to Host Webinar Announcing Lead In Vivo Development CandidateGlobeNewsWire • 08/28/25